Access to Cutting Edge Imaging Technologies in Europe

Imaging techniques from microscopy to computer tomography are key tools for all life scientists to understand living systems. The availability of cutting edge imaging technologies is becoming a critical factor for success in science and human health care, but access to advanced technology expertise in imaging is often limited. Euro-BioImaging, a project on the roadmap of the European Strategy Forum on Research Infrastructures (ESFRI), aims to provide scientists throughout Europe with open access to state-of-the-art imaging technologies at all levels of biological and biomedical research, from bench to bedside. On December 1st 2010 the project started with an initial 3-year preparatory phase, which is funded under the 7th Framework Programme of the European Union.

"The coordinated and harmonised deployment of imaging infrastructure under the Euro-BioImaging umbrella significantly addresses the fragmentation of such efforts currently present in Europe and will facilitate the translation from basic results to medical applications," says Stefan Schönberg from the European Institute for Biomedical Imaging Research (EIBIR), scientific coordinator for medical imaging, who is based at the Medical Faculty Mannheim.

In its preparatory phase Euro-BioImaging will develop a plan to construct and operate a set of complementary and strongly interlinked imaging infrastructure facilities. This plan will be based on a comprehensive assessment of researchers' needs in terms of access, service, and training. Euro-BioImaging will also establish the legal, governmental and financial framework for such infrastructures, and seek agreements with funding bodies. Eligibility criteria for participating facilities will be defined, an independent evaluation panel will be established, and a call for applications will be announced.

"Euro-BioImaging will support research, training and innovation in biological and biomedical imaging on a pan-European level, and provide a clear path of access to imaging technologies for every biomedical scientist in Europe," says Jan Ellenberg from the European Molecular Biology Laboratory (EMBL), scientific coordinator for biological imaging.

At the kick-off meeting on January 17th 2011 Euro-BioImaging has assembled its 39 core partners to set the course for a successful accomplishment of the first year's project goals. The focus will be on the consultation with stakeholders and the evaluation of European researchers' demands for imaging infrastructure.

For further information, please visit:
http://www.eurobioimaging.eu

About Euro-BioImaging
Euro-BioImaging is one of 10 Biological and Medical Sciences Projects included in the roadmap of the European Strategy Forum on Research Infrastructures (ESFRI). It is scientifically coordinated by the European Institute for Biomedical Imaging Research, EIBIR (Medical Imaging) and the European Molecular Biology Laboratory, EMBL (Biological Imaging).

The Euro-BioImaging Preparatory Phase consortium comprises 39 core partners and more than 180 associate partner institutions from 24 countries. The broad interest in this research infrastructure even at an early stage of the project clearly indicates the pan-European support for the vision of Euro-BioImaging.

About EIBIR
The European Institute for Biomedical Imaging Research (EIBIR) is a non-profit limited liability company that was founded in 2006 by the European Society of Radiology (ESR), dedicated to the co-ordination of research. EIBIR has the aim of co-ordinating and supporting the development of biomedical imaging technologies and the dissemination of knowledge with the ultimate goal of improving diagnosis, treatment and prevention of disease. The platform supports networking activities in research and is key to spreading good practice, promoting common initiatives and interoperability in the field of biomedical imaging research. This will generate critical mass and help coordinate research into new instrumentation, new methods, concepts and technologies. EIBIR currently has over 280 member institutions, two thirds of which are made up by clinical departments and one third by basic science laboratories. EIBIR has six shareholder organisations in addition to ESR: CIRSE; ESMRMB, EANM, EFOMP, COCIR, and EORTC.

Most Popular Now

Clanwilliam Brings Epic Care to the UK

Care homes looking to digitise their administration and care procedures have a new option with the launch of Epic Care in the UK. Epic Care is a modular, scalable system developed...

AI Language Models Write Good Doctor…

Generative AI should be able to write usable doctor's letters and thus potentially speed up medical documentation, according to a study by the University Medical Center Freiburg. Around 93% of...

West Yorkshire and Harrogate Hospitals S…

Clinicians working at five of the six trusts in the West Yorkshire Association of Acute Trusts (WYAAT) can access test results from across their pathology network, following a summer roll-out...

ChatGPT Shows Human-Level Assessment of …

As artificial intelligence advances, its uses and capabilities in real-world applications continue to reach new heights that may even surpass human expertise. In the field of radiology, where a correct...

When Detecting Depression, the Eyes have…

It has been estimated that nearly 300 million people, or about 4% of the global population, are afflicted by some form of depression. But detecting it can be difficult, particularly...

When it comes to Emergency Care, ChatGPT…

If ChatGPT were cut loose in the Emergency Department, it might suggest unneeded x-rays and antibiotics for some patients and admit others who didn't require hospital treatment, a new study...

HWL 2024 Brings Together a Record Number…

1 - 2 October 2024, Luxembourg. The second edition of Healthcare Week Luxembourg on 1 and 2 October 2024, organised by the Federation of Luxembourg Hospitals (FHL), in partnership with the...

AI Drives Development of Cancer Fighting…

University of Houston researchers and their students are developing a new software technology, based on artificial intelligence, for advancing cell-based immunotherapy to treat cancer and other diseases. CellChorus...

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

Revolutionizing Cardiovascular Risk Asse…

A recent position paper in the Asia-Pacific Journal of Ophthalmology explores the transformative potential of artificial intelligence (AI) in ophthalmology. Led by Lama Al-Aswad, Professor of Ophthalmology and Irene Heinz...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Why the NHS Needs a Transparency Revolut…

Opinion Article by Dr Mark Ratnarajah, NHS paediatrician and UK Managing Director for C2-Ai. Wes Streeting wanted 'no stone left unturned' when he asked Lord Darzi to examine the current state...